These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16601761)

  • 1. Matrix metalloproteinases and their function in myocardium.
    Kukacka J; Průsa R; Kotaska K; Pelouch V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):225-36. PubMed ID: 16601761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
    Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
    Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG; Coker ML; Bond BR; Zellner JL
    Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial extracellular matrix remodeling in ischemic heart failure.
    Gallagher GL; Jackson CJ; Hunyor SN
    Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY; McTiernan CF; Feldman AM
    Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP induction and inhibition in myocardial infarction.
    Lindsey ML
    Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.
    El Hajj EC; El Hajj MC; Ninh VK; Gardner JD
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H463-H473. PubMed ID: 29775412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
    Pauschinger M; Chandrasekharan K; Schultheiss HP
    Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors.
    Smith MF; Ricke WA; Bakke LJ; Dow MP; Smith GW
    Mol Cell Endocrinol; 2002 May; 191(1):45-56. PubMed ID: 12044918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metaloproteinases in vascular pathology.
    Simões G; Pereira T; Caseiro A
    Microvasc Res; 2022 Sep; 143():104398. PubMed ID: 35671836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and Function of Human Matrix Metalloproteinases.
    Laronha H; Caldeira J
    Cells; 2020 Apr; 9(5):. PubMed ID: 32357580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibition and the prevention of heart failure.
    Lee RT
    Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S; Lijnen HR
    Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
    Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How could analyzing the activity of two matrix metalloproteinases unveil the cause of sudden cardiac death.
    Sosa I; Grubesic A
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):712-714. PubMed ID: 27271976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavior of Metalloproteinases in Adipose Tissue, Liver and Arterial Wall: An Update of Extracellular Matrix Remodeling.
    Berg G; Barchuk M; Miksztowicz V
    Cells; 2019 Feb; 8(2):. PubMed ID: 30769840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.